SynthesisInvestigational new drugs2017
Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials.
Meihui Cao et al.PubMed ↗Publisher ↗
No numbers read from the abstract.